This study identified and validated novel promoter DNA hypermethylation signatures as prognostic biomarkers in oral squamous cell carcinoma (OSCC). Combining a discovery approach based on pharmacologic demethylation and RNA sequencing with multi-platform validation, five candidate genes (GPX3, ANG, CTGF, GPRC5B, BAMBI) were identified. Their promoter hypermethylation is associated with cancer-specific transcriptional and protein silencing. Notably, CTGF hypermethylation was independently associated with poor overall survival, and a combined ANG+CTGF signature demonstrated superior and reproducible prognostic performance. These findings pave the way for clinical risk stratification in OSCC patients.
This retrospective study investigated the spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma (OSCC) by comparing primary tumors and matched lymph node metastases. Findings revealed that both PD-L1 and c-MET were frequently expressed in primary tumors but at significantly lower levels in corresponding lymph node metastases. A substantial discordance in PD-L1 CPS status was observed between the two tumor compartments, potentially impacting biomarker classification. While higher PD-L1 expression in primary tumors was associated with nodal metastasis, no significant correlation was found between PD-L1 and c-MET. These results highlight the critical role of spatial heterogeneity in biomarker assessment for OSCC.
This retrospective study compared the clinicopathological features of stage I-II oral squamous cell carcinoma (OSCC) in adolescents and young adults (AYAs) versus older patients. OSCCs in AYAs are more frequently located on the tongue and exhibit distinct histological patterns, including an abnormal TP53 immunophenotype. Although AYAs demonstrate significantly better overall and disease-free survival, a depth of invasion (DOI) greater than 5 mm is a major prognostic indicator for distant metastasis and poorer survival within this group. Other factors such as clinical stage, tumor thickness, and tumor budding may also predict the risk of postoperative lymph node metastasis. Tested molecular markers did not provide robust prognostic stratification.
This study investigated the TP53 mutation landscape in oral squamous cell carcinoma (OSCC) and its association with patient survival. Using next-generation sequencing on 124 samples, pathogenic TP53 mutations were detected in 65% of patients, encompassing 75 distinct variant patterns. Patients harboring these mutations exhibited significantly shorter cancer-specific survival, particularly those with advanced-stage (III/IV) disease. Truncating or splice mutations were associated with an even worse prognosis. These findings highlight the importance of TP53-based molecular classification for developing novel precision strategies against OSCC.